This retrospective study of 97 treatment-naïve patients with PAH in NYHA/WHO FC III or IV investigated initial dual oral combination therapy with an ERA (bosentan or ambrisentan) and a PDE-5 inhibitor (sildenafil or tadalafil). Here, PDE5A is linked to pulmonary arterial hypertension.